GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Protagenic Therapeutics Inc (NAS:PTIX) » Definitions » Cyclically Adjusted Book per Share

Protagenic Therapeutics (Protagenic Therapeutics) Cyclically Adjusted Book per Share : $6.74 (As of Dec. 2023)


View and export this data going back to 2003. Start your Free Trial

What is Protagenic Therapeutics Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Protagenic Therapeutics's adjusted book value per share for the three months ended in Dec. 2023 was $0.827. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $6.74 for the trailing ten years ended in Dec. 2023.

During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -84.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Protagenic Therapeutics was -9.60% per year. The lowest was -84.90% per year. And the median was -27.55% per year.

As of today (2024-04-30), Protagenic Therapeutics's current stock price is $1.41. Protagenic Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $6.74. Protagenic Therapeutics's Cyclically Adjusted PB Ratio of today is 0.21.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Protagenic Therapeutics was 0.26. The lowest was 0.00. And the median was 0.00.


Protagenic Therapeutics Cyclically Adjusted Book per Share Historical Data

The historical data trend for Protagenic Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Protagenic Therapeutics Cyclically Adjusted Book per Share Chart

Protagenic Therapeutics Annual Data
Trend Jun14 Jun15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,192.16 1,944.23 1,849.99 -2,287.01 6.74

Protagenic Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2,287.01 -293.99 7.02 6.92 6.74

Competitive Comparison of Protagenic Therapeutics's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Protagenic Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Protagenic Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Protagenic Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Protagenic Therapeutics's Cyclically Adjusted PB Ratio falls into.



Protagenic Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Protagenic Therapeutics's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book= Book Value per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.827/129.4194*129.4194
=0.827

Current CPI (Dec. 2023) = 129.4194.

Protagenic Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201403 0.000 99.695 0.000
201406 -4.000 100.560 -5.148
201409 -21.231 100.428 -27.360
201412 -41.692 99.070 -54.464
201503 -60.000 99.621 -77.947
201506 -77.231 100.684 -99.273
201509 -97.385 100.392 -125.544
201512 -121.692 99.792 -157.821
201603 464.000 100.470 597.694
201606 148.095 101.688 188.482
201609 1.415 101.861 1.798
201612 0.966 101.863 1.227
201703 0.849 102.862 1.068
201706 0.732 103.349 0.917
201709 0.656 104.136 0.815
201712 0.475 104.011 0.591
201803 0.376 105.290 0.462
201806 0.218 106.317 0.265
201809 0.126 106.507 0.153
201812 -0.082 105.998 -0.100
201903 -0.141 107.251 -0.170
201906 -0.148 108.070 -0.177
201909 -0.142 108.329 -0.170
201912 -0.247 108.420 -0.295
202003 -0.228 108.902 -0.271
202006 -0.291 108.767 -0.346
202009 -0.394 109.815 -0.464
202012 -0.444 109.897 -0.523
202103 -0.748 111.754 -0.866
202106 2.656 114.631 2.999
202109 2.447 115.734 2.736
202112 2.311 117.630 2.543
202203 2.022 121.301 2.157
202206 1.911 125.017 1.978
202209 1.708 125.227 1.765
202212 1.601 125.222 1.655
202303 1.484 127.348 1.508
202306 1.250 128.729 1.257
202309 0.959 129.860 0.956
202312 0.827 129.419 0.827

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Protagenic Therapeutics  (NAS:PTIX) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Protagenic Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=1.41/6.74
=0.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Protagenic Therapeutics was 0.26. The lowest was 0.00. And the median was 0.00.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Protagenic Therapeutics Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Protagenic Therapeutics's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Protagenic Therapeutics (Protagenic Therapeutics) Business Description

Traded in Other Exchanges
Address
149 Fifth Avenue, Suite 500, New York, NY, USA, 10010
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression and neurodegenerative disorders by using peptide-based and brain active therapeutics. The company's lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.
Executives
Alexander K. Arrow officer: Chief Financial Officer PO BOX 3094, REDWOOD CITY CA 94064
Jennifer Buell director 3 FORBES ROAD, LEXINGTON MA 02421
Brian Corvese director C/O ANTIGENICS INC., 162 FIFTH AVENUE, SUITE 900, NEW YORK NY 10010
Robert Benjamin Stein director C/O AGENUS INC., 3 FORBES ROAD, LEXINGTON MA 02421
Khalil Barrage director 149 FIFTH AVENUE, SUITE 500, NEW YORK NY 10010
Gregory Ekizian director 149 FIFTH AVENUE, SUITE 500, NEW YORK NY 10010
Robert Ziroyan officer: COO / Interim President 149 FIFTH AVENUE, SUITE 500, NEW YORK NY 10010
Joshua Silverman director IROQUOIS CAPITAL MANAGEMENT LLC, 205 EAST 42ND ST - 20TH FL., NEW YORK NY 10017
Garo H Armen director, 10 percent owner, officer: See Remarks 3 FORBES ROAD, LEXINGTON MA 02421
Edward J Gildea director, officer: Chief Executive Officer C/O CONVERTED ORGANICS INC., 7A COMMERCIAL WHARF WEST, BOSTON MA 02110
David J Horin officer: Chief Financial Officer 1270 AVENUE OF THE AMERICAS, 16TH FLOOR, NEW YORK NY 10020
Jonathan Schechter director C/O ATRINSIC, INC. 1 GRAND CENTRAL PLACE, SUITE 2319, NEW YORK NY 10165
Nathan Yu-gai Fong officer: Chief Financial Officer THE ORCHARD ENTERPRISES, INC., 23 E. 4TH ST., 3RD FL., NEW YORK NY 10003
Sharon Siegel officer: Chief Marketing Officer C/O ATRINSIC, INC., 469 SEVENTH AVENUE, 10TH FLOOR, NEW YORK NY 10018
Raymond Musci director, officer: Exec VP, Corporate Development C/O BRILLIANT DIGITAL ENTERTAINMENT INC, 6355 TOPANGA CANYON BOULEVARD SUITE 520, WOODLAND HILLS CA 91367

Protagenic Therapeutics (Protagenic Therapeutics) Headlines

From GuruFocus